Shanghai Hengrui Pharmaceutical Co., Ltd.
This trial was designed to evaluate the efficacy and safety of SHR-1819 injection in patients with atopic dermatitis
Moderate to Severe Atopic Dermatitis
SHR1819
Placebo
Phase 2
Study Type : | Interventional |
Estimated Enrollment : | 158 participants |
Masking: | Single |
Primary Purpose: | Treatment |
Official Title: | A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacokinetics of SHR-1819 Injection in Adults With Moderate to Severe Atopic Dermatitis |
Actual Study Start Date : | October 8, 2022 |
Estimated Primary Completion Date : | September 15, 2023 |
Estimated Study Completion Date : | November 23, 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: Treatment group A:SHR-1819 |
Drug: SHR1819 |
Experimental: Treatment group B:SHR-1819 |
Drug: SHR1819 |
Experimental: Treatment group C:SHR-1819 |
Drug: SHR1819 |
Placebo Comparator: Treatment group D:placebo |
Drug: Placebo |
Ages Eligible for Study: | 18 Years to 75 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
Huashan Sub-Hospital of Fudan University
Shanghai, Shanghai, China, 200040